Get started
Author

Matteo Duca

Observed names: Duca Matteo, Duca, Matteo, M Duca, M. Duca, matteo Duca
ORCID: 0000-0003-3968-5011
Observed ORCID: 0000-0003-3968-5011
OpenAlex ID: A5050911840
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
2017 · Alexander Drilon, Salvatore Siena, et al. · Cancer Discovery · 827
PDF
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
2013 · Fabio Conforti, Chiara Catania, et al. · Lung Cancer · 43
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
2018 · Anna Tessari, Lorenzo Pilla, et al. · The Breast · 38
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care
2023 · Andrea Vingiani, Luca Agnelli, et al. · JCO Precision Oncology · 26
PDF
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
2024 · Licia Rivoltini, Chiara Camisaschi, et al. · Scientific Reports · 12
PDF
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
2022 · Iolanda Capone, Fabio Bozzi, et al. · Exploration of Targeted Anti-tumor Therapy · 11
PDF
Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project
2023 · Paola Mosconi, Cinzia Colombo, et al. · BMC Cancer · 9
PDF
Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer
2016 · Francesco Gelsomino, Maria Rita Castellani, et al. · Journal of Thoracic Disease · 9
PDF
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations
2025 · Federico Nichetti, Marta Brambilla, et al. · JCO Precision Oncology · 8
Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma
2021 · Vincent Ribrag, Jean-Marie Michot, et al. · Blood · 8
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
2022 · Jacopo Azzollini, Andrea Vingiani, et al. · Frontiers in Oncology · 6
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors
2020 · Filippo de Braud, Jean-Pascal H. Machiels, et al. · Cancers · 6
PDF
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
2021 · Margherita Ambrosini, Giovanni Fucà, et al. · Critical Reviews in Oncology/Hematology · 5
Metastatic Breast Cancer Treated with Lapatinib with a Prolonged Benefit: A Case Report and a Review of Therapeutic Options Available
2013 · Giulia Valeria Bianchi, Matteo Duca, et al. · Tumori Journal · 5
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study
2019 · Gabriella Mariani, Giulia Galli, et al. · The Breast Journal · 4
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study
2025 · E. Colombo, S. Cavalieri, et al. · ESMO Open · 3
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization
2025 · Daniele Lorenzini, Rebecca Salvatori, et al. · Tumori Journal · 3
Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach
2023 · Leonardo Provenzano, Silvia Damian, et al. · Journal of Thoracic Oncology · 3
PDF
Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
2026 · Geoffrey Liu, Alexander E. Drilon, et al. · Cancer Research · 2
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
2024 · Jacopo Azzollini, Iolanda Capone, et al. · Tumori Journal · 2
Skip pattern approach toward the early access of innovative anticancer drugs
2021 · G. Apolone, A. Ardizzoni, et al. · ESMO Open · 2
PDF
Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?
2018 · E. Farè, S. Sdao, et al. · Annals of Oncology · 2
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors.
2016 · Filippo G. De Braud, Jean-Pascal H. Machiels, et al. · Journal of Clinical Oncology · 2
ICIs Exceptional Long Response in TNBC : Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature
2025 · Simone Rota, Carolina Sciortino, et al. · Cancer Reports · 1
PDF
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials
2024 · Luca Agnelli, Andrea Villa, et al. · Tumori Journal · 1
Works count: 81
Citation count: 1,044
H-index: 8
I10-index: 6
Year
Topic
Type